Press Release

PhRMA Statement on New FDA Initiative

PhRMA April 30, 2013

Washington, D.C. (May 11, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson today released the following statement:

“America’s pharmaceutical research and biotechnology companies are committed to communicating truthful, scientifically accurate information in all direct-to-consumer (DTC) advertising and interactions with healthcare professionals. In fact, companies devote substantial time and effort, and often ask for input from the Food and Drug Administration (FDA), to ensure that prescription drug communications are accurate and meet all applicable legal requirements.

“We view today’s announcement by FDA as another step to help educate – and receive feedback from – healthcare providers about prescription drug advertising and promotion. We should note that PhRMA has also worked with many healthcare stakeholders, including providers, to obtain their input to help strengthen our recently revised Guiding Principles on Direct to Consumer Advertisements about Prescription Medicines and PhRMA Code on Interactions with Healthcare Professionals.

“Prescription drug advertising and promotion can provide great value to patient care and the U.S. health care system. In fact, studies have shown that DTC advertising informs patients potentially suffering from an undiagnosed condition, raises awareness of treatment options, and also benefits the U.S. healthcare system by encouraging patients to seek medical attention that may help manage conditions and avoid the need for hospitalization or surgery.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For more information on public health emergencies, visit:

For information on the danger of imported drugs, visit: